精细TACE的治疗目标与栓塞终点
收稿日期: 2022-01-24
网络出版日期: 2022-06-16
基金资助
复旦大学附属中山医院青年基金(2020ZSQN77)
Precision transarterial chemoembolization: treatment goal and embolic endpoint
马婧嶔, 杨敏捷, 颜志平 . 精细TACE的治疗目标与栓塞终点[J]. 外科理论与实践, 2022 , 27(02) : 131 -133 . DOI: 10.16139/j.1007-9610.2022.02.009
| [1] | Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):209-249. |
| [2] | Benson AB, D′Angelica MI, Abbott DE, et al. Hepatobi-liary cancers, version 2.2021, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2021, 19(5):541-565. |
| [3] | 中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗指南(2022年版)[J]. 中国实用外科杂志, 2022, 42(3):241-273. |
| [4] | 马婧嶔, 颜志平. 肝癌介入治疗进一步思考[J]. 介入放射学杂志, 2019, 28(6):507-510. |
| [5] | 张雯, 周永杰, 颜志平. 再论精细TACE[J]. 介入放射学杂志, 2021, 30(10):971-975. |
| [6] | Kudo M, Han KH, Ye SL, et al. A changing paradigm for the treatment of intermediate-stage hepatocellular carcinoma: Asia-Pacific primary liver cancer expert consensus statements[J]. Liver Cancer, 2020, 9(3):245-260. |
| [7] | Lencioni R, de Baere T, Soulen MC, et al. Lipiodol transarterial chemoembolization for hepatocellular carcinoma: a systematic review of efficacy and safety data[J]. Hepatology, 2016, 64(1):106-116. |
| [8] | Bolondi L, Burroughs A, Dufour JF, et al. Heterogeneity of patients with intermediate (BCLC B) hepatocellular carcinoma: proposal for a subclassification to facilitate treatment decisions[J]. Semin Liver Dis, 2012, 32(4):348-359. |
| [9] | Piscaglia F, Ogasawara S. Patient selection for transarterial chemoembolization in hepatocellular carcinoma: importance of benefit/risk assessment[J]. Liver Cancer, 2018, 7(1):104-119. |
| [10] | Chang Y, Jeong SW, Jang JY, et al. Recent updates of transarterial chemoembolilzation in hepatocellular carcinoma[J]. Int J Mol Sci, 2020, 21(21):8165. |
| [11] | Yang K, Sung PS, You YK, et al. Pathologic complete response to chemoembolization improves survival outcomes after curative surgery for hepatocellular carcinoma: predictive factors of response[J]. HPB (Oxford), 2019, 21(12):1718-1726. |
| [12] | Frenette CT, Osorio RC, Stark J, et al. Conventional TACE and drug-eluting bead TACE as locoregional the-rapy before orthotopic liver transplantation: comparison of explant pathologic response[J]. Transplantation, 2014, 98(7):781-787. |
| [13] | Sato Y, Watanabe H, Sone M, et al. Tumor response evaluation criteria for HCC (hepatocellular carcinoma) treated using TACE (transcatheter arterial chemoembolization): RECIST (response evaluation criteria in solid tumors) version 1.1 and mRECIST (modified RECIST): JIVROSG-0602[J]. Ups J Med Sci, 2013, 118(1):16-22. |
| [14] | Bannangkoon K, Hongsakul K, Tubtawee T, et al. Rate and predictive factors for sustained complete response after selective transarterial chemoembolization(TACE) in patients with hepatocellular carcinoma[J]. Asian Pac J Cancer Prev, 2018, 19(12):3545-3550. |
| [15] | Saito N, Tanaka T, Nishiohuku H, et al. Transarterial- chemoembolization remains an effective therapy for intermediate-stage hepatocellular carcinoma with preserved liver function[J]. Hepatol Res, 2020, 50(10):1176-1185. |
| [16] | Lencioni R, Petruzzi P, Crocetti L. Chemoembolization of hepatocellular carcinoma[J]. Semin Intervent Radiol, 2013, 30(1):3-11. |
| [17] | Terayama N, Matsui O, Gabata T, et al. Accumulation of iodized oil within the nonneoplastic liver adjacent to hepatocellular carcinoma via the drainage routes of the tumor after transcatheter arterial embolization[J]. Car-diovasc Intervent Radiol, 2001, 24(6):383-387. |
| [18] | Miyayama S. Ultraselective conventional transarterial chemoembolization: when and how?[J]. Clin Mol Hepatol, 2019, 25(4):344-353. |
| [19] | Miyayama S, Matsui O, Yamashiro M, et al. Ultraselective transcatheter arterial chemoembolization with a 2-f tip microcatheter for small hepatocellular carcinomas: relationship between local tumor recurrence and visualization of the portal vein with iodized oil[J]. J Vasc Interv Radiol, 2007, 18(3):365-376. |
| [20] | Bannangkoon K, Hongsakul K, Tubtawee T, et al. Safety margin of embolized area can reduce local recurrence of hepatocellular carcinoma after superselective transarterial chemoembolization[J]. Clin Mol Hepatol, 2019, 25(1):74-85. |
| [21] | Miyayama S, Yamashiro M, Ikeda R, et al. Efficacy of superselective conventional transarterial chemoembolization using guidance software for hepatocellular carcinoma within three lesions smaller than 3 cm[J]. Cancers (Basel), 2021, 13(24):6370. |
/
| 〈 |
|
〉 |
